AKAlexandra Kolas

Alexandra Kolas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Kolas has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Norditerpene Natural Products from Subterranean Fungi with Anti-Parasitic Activity

    by Alexandra Kolas, Yudi Rusman, Ana C. R. G. Maia, Jessica M. Williams, Jiashu Xie, Roshan Katekar, Fernanda G. Fumuso, Alexis Cotto-Rosario, Chidiebere N. Onoh, Hanen Baggar, et al.

    Cryptosporidium is a waterborne gastrointestinal parasite that causes diarrheal disease worldwide. Currently, there are no effective therapeutics to treat cryptosporidiosis. Since natural products are a known source of anti-parasitic compounds, we screened a library of extracts and pure compounds isolated from bacteria and fungi collected from subterranean environments for anti-Cryptosporidium activity. Seven norditerpene lactones isolated from the fungus Oidiodendron truncatum collected from the Soudan Iron mine in Minnesota showed potent activity and were further tested to identify the most active compounds. The availability of a diverse suite of natural structural analogs with varying activities allowed us to determine some structure–activity relationships for both anti-parasitic activity and cytotoxicity. The two most potent compounds, oidiolactones A and B, had EC50s against C. parvum of 530 and 240 nM, respectively, without cytotoxicity to host cells. Both compounds also inhibited the related parasite Toxoplasma gondii. Oidiolactone A was active against asexual, but not sexual, stages of C. parvum, and killed parasites within 8 h of treatment. This compound reduced C. parvum infection by 70% in IFNγ−/− mice, with no signs of toxicity. The high potency, low cytotoxicity, and in vivo activity combined with high production and synthetic accessibility make these oidiolactones attractive scaffolds for the development of new anti-Cryptosporidium therapeutics.